Ignite Creation Date:
2024-05-06 @ 7:30 PM
Last Modification Date:
2024-10-26 @ 3:08 PM
Study NCT ID:
NCT06039631
Status:
RECRUITING
Last Update Posted:
2023-09-15
First Post:
2023-09-09
Brief Title:
Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In LaryngealHypopharyngeal Cancer
Sponsor:
Fudan University
Organization:
Fudan University
Study Overview
Official Title:
Neoadjuvant Immunotherapy And Chemotherapy Followed By Concurrent Chemoradiation Or Organ Preservation Surgery In Locally Advanced Laryngeal Cancer And Hypopharyngeal Cancer
Status:
RECRUITING
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In the global landscape of cancer head and neck malignancies are highly prevalent with 878000 new cases and 444000 deaths recorded in 2020 Notably laryngeal and hypopharyngeal cancers contribute to around 30 of these instances More than 50 of patients are diagnosed with locally advanced disease necessitating intensive treatments that significantly impact their quality of life Despite these efforts the prognosis for laryngeal and hypopharyngeal cancers remains grim with a 5-year survival rate of 30 to 50
Past approaches focused on preserving laryngeal function and patient well-being including minimally invasive surgery advanced radiotherapy and induction chemotherapy Our prior research highlighted the effectiveness of combining toripalimab-based induction therapy and chemotherapy followed by concurrent chemoradiotherapy or surgery Positive short-term outcomes and manageable side effects were observed with encouraging larynx preservation rates after one year
Against this backdrop the current study aims to explore neoadjuvant immunotherapy combined with chemotherapy for patients with locally advanced laryngeal and hypopharyngeal cancer It seeks to compare the therapeutic efficacy and quality of life impacts of concurrent radiochemotherapy and organ-preserving surgery The ultimate goal is to identify optimal strategies for future interventions
Past approaches focused on preserving laryngeal function and patient well-being including minimally invasive surgery advanced radiotherapy and induction chemotherapy Our prior research highlighted the effectiveness of combining toripalimab-based induction therapy and chemotherapy followed by concurrent chemoradiotherapy or surgery Positive short-term outcomes and manageable side effects were observed with encouraging larynx preservation rates after one year
Against this backdrop the current study aims to explore neoadjuvant immunotherapy combined with chemotherapy for patients with locally advanced laryngeal and hypopharyngeal cancer It seeks to compare the therapeutic efficacy and quality of life impacts of concurrent radiochemotherapy and organ-preserving surgery The ultimate goal is to identify optimal strategies for future interventions
Detailed Description:
Head and neck cancer stands as one of the most prevalent forms of malignancy on a global scale Among these head and neck squamous cell carcinoma HNSCC takes precedence as the predominant histological subtype encompassing around 90 of the total caseload Notably laryngeal and hypopharyngeal cancer contribute to approximately 30 of these instances Upon initial diagnosis a striking majority-over 50 of patients find themselves grappling with locally advanced disease necessitating an assertive therapeutic approach that significantly impacts their overall quality of life Despite the rigor of these treatments the prognosis for laryngeal and hypopharyngeal cancer remains discouraging characterized by a 5-year overall survival rate ranging between 30 and 50
Past endeavors have been dedicated to preserving laryngeal function and enhancing the well-being of patients spanning from the adoption of minimally invasive and organ-conserving surgical techniques to advancements in radiotherapy and the advent of induction chemotherapy Recent strides in immunotherapy particularly the integration of programmed cell death protein-1 PD-1 inhibitors have brought about a remarkable paradigm shift in how recurrentmetastatic HNSCC is managed Our previous investigation underscored the efficacy of the strategy involving the combination of toripalimab-based induction therapy and chemotherapy followed by concurrent chemoradiotherapy or surgical intervention showcasing favorable short-term outcomes and manageable adverse effects The data further revealed highly promising larynx preservation rates at the one-year mark
Given this backdrop the present study seeks to delve into patients experiencing partial relief through neoadjuvant immunotherapy combined with chemotherapy in cases of locally advanced laryngeal and hypopharyngeal cancer The study aims to compare the therapeutic efficacy and discrepancies in quality of life resulting from concurrent radiochemotherapy and organ-preserving surgical treatment The overarching goal is to delineate optimal strategies for subsequent interventions
Past endeavors have been dedicated to preserving laryngeal function and enhancing the well-being of patients spanning from the adoption of minimally invasive and organ-conserving surgical techniques to advancements in radiotherapy and the advent of induction chemotherapy Recent strides in immunotherapy particularly the integration of programmed cell death protein-1 PD-1 inhibitors have brought about a remarkable paradigm shift in how recurrentmetastatic HNSCC is managed Our previous investigation underscored the efficacy of the strategy involving the combination of toripalimab-based induction therapy and chemotherapy followed by concurrent chemoradiotherapy or surgical intervention showcasing favorable short-term outcomes and manageable adverse effects The data further revealed highly promising larynx preservation rates at the one-year mark
Given this backdrop the present study seeks to delve into patients experiencing partial relief through neoadjuvant immunotherapy combined with chemotherapy in cases of locally advanced laryngeal and hypopharyngeal cancer The study aims to compare the therapeutic efficacy and discrepancies in quality of life resulting from concurrent radiochemotherapy and organ-preserving surgical treatment The overarching goal is to delineate optimal strategies for subsequent interventions
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None